World Health Organization site
Skip Navigation Links

Please fill this short user satisfaction survey


Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: EUCTR
Last refreshed on: 7 June 2021
Main ID:  EUCTR2019-001653-99-FR
Date of registration: 12/10/2020
Prospective Registration: Yes
Primary sponsor: Eli Lilly and Company
Public title: A placebo-controlled study of mirikizumab and vedolizumab in participants with moderately to severely active ulcerative colitis
Scientific title: A Phase 3b, Randomized, Double-Blind, Parallel-Arm, Placebo- and Active- Controlled Treat-Through Study of Mirikizumab and Vedolizumab in Participants with Moderately to Severely Active Ulcerative Colitis - LUCENT-ACT
Date of first enrolment: 26/11/2020
Target sample size: 1100
Recruitment status: Not Recruiting
URL:  https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-001653-99
Study type:  Interventional clinical trial of medicinal product
Study design:  Controlled: yes
Randomised: yes
Open: no
Single blind: no
Double blind: yes
Parallel group: yes
Cross over: no
Other: no
If controlled, specify comparator, Other Medicinial Product: no
Placebo: yes
Other: no
Number of treatment arms in the trial: 3
 
Phase:  Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): no Therapeutic confirmatory - (Phase III): yes Therapeutic use (Phase IV): no
Countries of recruitment
Argentina Australia Austria Belgium Brazil Canada Croatia Czech Republic
Denmark France Germany Hungary India Italy Japan Korea, Republic of
Latvia Lithuania Malaysia Mexico Netherlands Poland Portugal Romania
Russian Federation Serbia Slovakia South Africa Spain Switzerland Turkey Ukraine
United Kingdom United States
Contacts
Name: Clinical Trial Registry Office   
Address:  Lilly Corporate Center, DC 1526 IN 46285 Indianapolis United States
Telephone:
Email: EU_Lilly_clinical_Trials@Lilly.com
Affiliation:  Eli Lilly and Company
Name: Clinical Trial Registry Office   
Address:  Lilly Corporate Center, DC 1526 IN 46285 Indianapolis United States
Telephone:
Email: EU_Lilly_clinical_Trials@Lilly.com
Affiliation:  Eli Lilly and Company
Key inclusion & exclusion criteria
Inclusion criteria:
• Participants must have a diagnosis of UC for at least 3 months prior to baseline
• Participants must have a confirmed diagnosis of moderately or severely active UC, as assessed by the modified Mayo score (MMS)
• Participants must have demonstrated an inadequate response to, a loss of response to, or an intolerance to conventional or to biologic therapy for UC
• Participants must, if female, meet the contraception requirements

Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 1000
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 100

Exclusion criteria:
• Participants must not have a current diagnosis of Crohn’s disease or inflammatory bowel disease-unclassified (indeterminate colitis)
• Participants must not have had a previous colectomy
• Participants must not have current evidence of toxic megacolon
• Participants must not have prior exposure to anti-IL-23p19 antibodies (e.g. risankizumab, brazikumab, guselkumab or tildrakizumab), vedolizumab, or natalizumab
• Participants must not have prior clinical failure or intolerance to anti-IL12p40 antibodies (e.g. ustekinumab), anti-integrin antibodies other than vedolizumab and natalizumab (e.g. etrolizumab) or anti-integrin ligand antibodies (e.g. ontamalimab) within 4 weeks prior to screening endoscopy



Age minimum:
Age maximum:
Gender:
Female: yes
Male: yes
Health Condition(s) or Problem(s) studied
Moderately to Severely Active Ulcerative Colitis
MedDRA version: 20.1 Level: LLT Classification code 10045365 Term: Ulcerative colitis System Organ Class: 100000004856
Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Intervention(s)

Product Name: mirikizumab
Product Code: LY3074828
Pharmaceutical Form: Solution for infusion
INN or Proposed INN: MIRIKIZUMAB
CAS Number: 1884201-71-1
Current Sponsor code: LY3074828
Other descriptive name: MIRIKIZUMAB
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 20-
Pharmaceutical form of the placebo: Solution for infusion
Route of administration of the placebo: Intravenous use

Product Name: mirikizumab
Product Code: LY3074828
Pharmaceutical Form: Solution for injection
INN or Proposed INN: MIRIKIZUMAB
CAS Number: 1884201-71-1
Current Sponsor code: LY3074828
Other descriptive name: MIRIKIZUMAB
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 100-
Pharmaceutical form of the placebo: Solution for infusion
Route of administration of the placebo: Intravenous use
Pharmaceutical form of the placebo: Solution for injection
Route of administration of the placebo: Subcutaneous use

Trade Name: Entyvio
Product Name: vedolizumab
Pharmaceutical Form: Solution for infusion
INN or Proposed INN: vedolizumab
CAS Number: 943609-66-3
Other descriptive name: VEDOLIZUMAB
Concentration unit: mg milligram(s)
Concentration type: up to
Concentration number: 300-
Pharmaceutical form of the placebo: Solution for infusion
Route of administration of the placebo: Intravenous use

Primary Outcome(s)
Primary end point(s): • Percentage of Participants in Histologic Remission based on histology.
Timepoint(s) of evaluation of this end point: Week 12
Secondary Objective: To evaluate the efficacy of mirikizumab on endoscopic improvement.
To evaluate the efficacy of mirikizumab on histo-endo improvement.
Main Objective: To evaluate the efficacy of mirikizumab on histologic improvement
Secondary Outcome(s)
Timepoint(s) of evaluation of this end point: Week 52
Week 12 for Percentage of Participants with Clinical Response Clinical response based on MMS.
Secondary end point(s): Percentage of Participants in Symptomatic Remission
Symptomatic remission based on modified Mayo Score (MMS) stool frequency (SF) and rectal bleeding (RB) subscores.

Percentage of Participants in Clinical Remission
Clinical remission based on MMS.

Percentage of Participants in Endoscopic Remission
Endoscopic remission based on MMS ES.

Percentage of Participants with Clinical Response
Clinical response based on MMS.

Percentage of Participants with Corticosteroid (CS) Free Remission without Surgery (Subgroup of Participants on CS at Baseline)
CS free remission without surgery based on clinical remission, symptomatic remission and no CS use.

Percentage of Participants with Resolution of Extraintestinal Manifestations (EIMs) Among Those That had Them at Baseline
Percentage of participants with resolution of EIMs among those that had them at baseline.

Change from Baseline on the Inflammatory Bowel Disease Questionnaire (IBDQ) Score
Change from baseline on the IBDQ score.

Percentage of Participants Undergoing Surgery for UC (Including Colectomy)

Percentage of Participants Hospitalized for UC
Secondary ID(s)
2019-001653-99-CZ
I6T-MC-AMBI
Source(s) of Monetary Support
Eli Lilly and Company
Secondary Sponsor(s)
Ethics review
Status: Approved
Approval date: 26/11/2020
Contact:
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history Please fill this short user satisfaction survey